Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity Consistency of Bivalent HPV Vaccine (Cecolin) in Girls 9-14 Years
NCT05426148Phase 4Completed
- Sponsor
- Xiamen Innovax Biotech Co., Ltd.
- Start
- May 2020
- Primary completion
- Aug 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of recombinant human papillomavirus bivalent (types 16, 18) vaccine in cervical intraepithelial neoplasia (CIN), Cervical Cancer (CC), vaginal intraepithelial neoplasia (VAIN), vulvar intraepithelial neoplasia (VIN), human papillomavirus infection, sponsored by Xiamen Innovax Biotech Co., Ltd.. Started May 2020; status: completed.
02
Drugs
recombinant human papillomavirus bivalent (types 16, 18) vaccine
03
Conditions
cervical intraepithelial neoplasia (CIN)Cervical Cancer (CC)vaginal intraepithelial neoplasia (VAIN)vulvar intraepithelial neoplasia (VIN)human papillomavirus infection
Beyond the preview
Go deeper on NCT05426148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05426148.